Indeed, neuroprotective effects of PPARγ agonists, such as pioglitazone, have been observed during neural cell differentiation and death, and in inflammatory and neurodegenerative conditions, including amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson's disease models, as well as stroke [196, 197]. Here, PPARG is linked to Parkinson disease.